Risk factor
Limited default risk
Profitability factor
Very strong margins and returns
About
Bonesupport Holding AB (publ) is a specialized orthobiologics firm dedicated to the creation and global commercialization of injectable bioceramic bone graft substitutes, designed to effectively treat bone voids. Its innovative solutions are distributed across Europe, North America, and other international territories. The company's key offerings include CERAMENT Bone Void Filler, a synthetic, injectable material that is both moldable and drillable, formulated with hydroxyapatite, calcium sulfate, and the radiopaque agent iohexol. Furthermore, Bonesupport provides CERAMENT G, a ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Beyond its current product line, Bonesupport is actively engaged in preclinical research to develop novel candidates aimed at promoting bone regeneration. This research targets challenging conditions such as trauma, revision arthroplasty, chronic osteomyelitis, various oncological applications, and bone and foot infections often associated with diabetes. Established in 1999, the company is headquartered in Lund, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of BONEX.ST is 386 and suggests 16.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i